-+ 0.00%
-+ 0.00%
-+ 0.00%

MBX Biosciences Announces End-of-Phase 2 FDA Meeting Results and Provides Phase 3 Development Plan For Canvuparatide

Benzinga·03/09/2026 12:09:20
Listen to the news

Based on feedback from the FDA, MBX plans to advance once-weekly canvuparatide into a Phase 3 trial in the third quarter of 2026.